Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

2.

Harnessing the apoptotic programs in cancer stem-like cells.

Wang YH, Scadden DT.

EMBO Rep. 2015 Sep;16(9):1084-98. doi: 10.15252/embr.201439675. Epub 2015 Aug 7. Review.

3.

Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

Vachhani P, Bose P, Rahmani M, Grant S.

Physiol Genomics. 2014 Jul 1;46(13):448-56. doi: 10.1152/physiolgenomics.00173.2013. Epub 2014 May 13. Review.

4.

Evading apoptosis in cancer.

Fernald K, Kurokawa M.

Trends Cell Biol. 2013 Dec;23(12):620-33. doi: 10.1016/j.tcb.2013.07.006. Epub 2013 Aug 16. Review.

5.

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration.

Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ.

Oncotarget. 2013 Aug;4(8):1241-52.

6.
7.

Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer.

Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA, Hann SR, Craig RW.

PLoS One. 2012;7(10):e47060. doi: 10.1371/journal.pone.0047060. Epub 2012 Oct 9.

8.

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.

Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T.

Blood Cancer J. 2012 Mar;2(3):e60. doi: 10.1038/bcj.2012.5. Epub 2012 Mar 9.

9.

The essential role of evasion from cell death in cancer.

Kelly GL, Strasser A.

Adv Cancer Res. 2011;111:39-96. doi: 10.1016/B978-0-12-385524-4.00002-7. Review.

10.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S.

Leuk Res. 2010 Mar;34(3):379-86. doi: 10.1016/j.leukres.2009.07.013. Epub 2010 Feb 1.

11.

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.

Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA.

Blood. 2009 Nov 12;114(20):4441-50. doi: 10.1182/blood-2009-07-233718. Epub 2009 Sep 17.

12.

Cited2 is required for normal hematopoiesis in the murine fetal liver.

Chen Y, Haviernik P, Bunting KD, Yang YC.

Blood. 2007 Oct 15;110(8):2889-98. Epub 2007 Jul 20.

13.

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC.

Cancer Cell. 2006 Nov;10(5):389-99.

14.

Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells.

Ito S, Mantel CR, Han MK, Basu S, Fukuda S, Cooper S, Broxmeyer HE.

Blood. 2007 Mar 1;109(5):1923-30. Epub 2006 Oct 12.

15.

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.

BMC Cancer. 2006 Oct 2;6:232.

16.

Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP.

Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF.

Mol Cell Biol. 2005 Apr;25(8):3117-26.

17.

AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2.

Fahy BN, Schlieman M, Virudachalam S, Bold RJ.

Br J Cancer. 2003 Jul 21;89(2):391-7.

18.

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.

Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X.

Genes Dev. 2003 Jun 15;17(12):1475-86. Epub 2003 Jun 3.

20.

Activation of adherent vascular neutrophils in the lung during acute endotoxemia.

Sunil VR, Connor AJ, Zhou P, Gordon MK, Laskin JD, Laskin DL.

Respir Res. 2002;3:21. Epub 2002 Aug 7.

Supplemental Content

Support Center